Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
IDXG Stock Summary
Top 10 Correlated ETFs
In the News
Interpace Biosciences Announces New $7.5 Million Credit Facility with Comerica Bank
PARSIPPANY, NJ, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a new $7.5 Million revolving credit facility with Comerica Bank (the “Bank”). The facility matures on September 30, 2023 and allows for advances based on 80% of eligible accounts receivable plus an applicable non-formula amount consisting of $2,000,000 of additional availability at close, stepping down $250,000 per quarter beginning with the quarter ending June 30, 2022. The interest rate is equal to prime plus .50%, prime being the greater of the bank's stated prime rate or the sum of the daily adjusting LIBOR rate, plus 2.5% per annum. The Bank will have a first priority security interest in substantially all of Interpace's and its subsidiaries' assets and will be senior to the existing $7.5 Million bridge loans made by the Company's private equity investors.
Interpace Biosciences, Inc. (IDXG) Reports Q2 Loss, Tops Revenue Estimates
Interpace Biosciences, Inc. (IDXG) delivered earnings and revenue surprises of -72.92% and 0.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Interpace Biosciences, Inc. (IDXG) Is a Great Choice for "Trend" Investors, Here's Why
Interpace Biosciences, Inc. (IDXG) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Interpace Biosciences Announces First Quarter 2021 Financial and Business Results
PARSIPPANY, NJ, May 11, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended March 31, 2021 and provided a business and financial update.
Interpace Biosciences Raises Full Year 2021 Revenue Guidance
Parsippany, NJ, April 19, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced an update to its full year 2021 revenue guidance originally provided on March 31, 2021.
Interpace Pharma Solutions Announces New Advanced Offering in RNA Biomarker Analysis
Parsippany, NJ, April 12, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today new capability in advancing RNA biomarker analysis for gene and cell-based therapies.
Interpace Biosciences Announces New PLA Code and Medicare Reimbursement Increase for Proprietary Thyroid Assay, ThyGeNEXT®
Parsippany, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that Novitas, its Medicare Administrative Contractor, has agreed to recognize the new Proprietary Laboratory Analysis (PLA) code that specifically identifies ThyGeNEXT® as a distinct test from any other test or service. PLA codes are an addition to the current procedural terminology (CPT®) code set approved by the American Medical Association CPT® Editorial Panel. PLA codes are alpha-numeric CPT codes with a corresponding descriptor for labs that want to more specifically identify their test. The new PLA code for ThyGeNEXT® is 0245U and the reimbursement for this code remains $2,919, representing a significant price increase over the prior reimbursement level of $560. In December, 2020, Novitas issued a new local coverage determination (LCD) for ThyGeNEXT® that reflects the test's enhanced mutation panel. In 2020, Interpace processed approximately 15,000 ThyGeNEXT® tests for over 700 physicians.
Interpace Biosciences Announces Full Year and Fourth Quarter 2020 Financial and Business Results
PARSIPPANY, NJ, March 31, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended December 31, 2020 and provided a business and financial update.
Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR
Part of Company's Site Consolidation and Cost Savings Measures
Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Illinois
In-network status for ThyGeNEXT® and ThyraMIR® with State's Largest Payer
IDXG Financial details
IDXG Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
|Revenue per share||7.78||6.43||8.04||9.99||7.51|
|Net income per share||-4.33||-7.11||-6.5||-3.57||-1.38|
|Operating cash flow per share||-3.08||-5.06||-3.62||-2.11||-1.82|
|Free cash flow per share||-3.24||-5.1||-4.01||-2.19||-1.89|
|Cash per share||2.16||0.62||0.69||0.8||1.14|
|Book value per share||11.7||3.48||-7.22||-10.26||-14.88|
|Tangible book value per share||1.1||-7.72||-12.13||-14.06||-15.09|
|Share holders equity per share||11.7||3.48||-7.22||-10.26||-14.88|
|Interest debt per share||0.12||2.01||1.31||3.54||4.03|
|Price to sales ratio||1.03||0.78||0.39||0.75||0.14|
|EV to sales||0.75||0.98||0.45||1||0.49|
|Enterprise value over EBITDA||-1.96||-1.17||-0.68||-5.05||-4.14|
|EV to operating cash flow||-1.9||-1.24||-1||-4.74||-2.04|
|EV to free cash flow||-1.8||-1.23||-0.91||-4.55||-1.96|
|Free cash flow yield||-0.4||-1.02||-1.28||-0.29||-1.82|
|Debt to equity||0.47||4.3||-2.57||-1.91||-1.25|
|Debt to assets||0.32||0.81||1.64||2.1||4.95|
|Net debt to EBITDA||0.72||-0.24||-0.09||-1.27||-2.98|
|Sales general and administrative to revenue||0.39||0.6||0.64||0.33||0.34|
|Research and developement to revenue||0.1||0.12||0.09||0.05||0.02|
|Intangibles to total assets||0.62||0.61||0.43||0.41||0.05|
|Capex to operating cash flow||0.05||0.01||0.11||0.04||0.04|
|Capex to revenue||-0.02||-0.01||-0.05||-0.01||-0.01|
|Capex to depreciation||-0.13||-0.03||-0.29||-0.07||-0.13|
|Stock based compensation to revenue||0.1||0.06||0.07||0.03||0.04|
|Return on tangible assets||-0.66||-0.98||-1.01||-0.65||-0.39|
|Tangible asset value||3.09M||-28.91M||-48.87M||-58.14M||-63.93M|
|Net current asset value||2.22M||-39.66M||-60.64M||-68.68M||-66.9M|
|Days sales outstanding||158.08||154.57||90.44||54.4||57.69|
|Days payables outstanding||37.91||110.55||75.97||42.08||28.17|
|Days of inventory on hand||0||41.93||34.56||27.9||32.83|
|Capex per share||-0.16||-0.03||-0.39||-0.09||-0.08|
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
|Revenue per share||2.47||2.21||1.93||1.95||2.28|
|Net income per share||-0.52||-0.92||-0.3||-0.33||0.08|
|Operating cash flow per share||-0.3||-0.69||-0.76||-0.06||0.26|
|Free cash flow per share||-0.3||-0.71||-0.77||-0.11||0.25|
|Cash per share||0.68||0.44||1.49||1.13||1.3|
|Book value per share||-10.54||-11.34||-14.52||-14.77||-14.52|
|Tangible book value per share||-14.15||-14.8||-14.8||-14.97||-14.65|
|Share holders equity per share||-10.54||-11.34||-14.52||-14.77||-14.52|
|Interest debt per share||3.48||3.83||3.21||3.83||3.69|
|Price to sales ratio||1.95||1.55||1.14||0.53||0.49|
|EV to sales||3.05||3.06||2||1.88||1.51|
|Enterprise value over EBITDA||-31.43||-9.16||-45.2||-21.48||14.1|
|EV to operating cash flow||-25.26||-9.8||-5.04||-56.9||13.07|
|EV to free cash flow||-24.89||-9.58||-4.98||-33.27||13.86|
|Free cash flow yield||-0.06||-0.21||-0.35||-0.11||0.22|
|Debt to equity||-1.87||-1.74||-1.25||-1.25||-1.25|
|Debt to assets||2.16||2.35||5.03||4.95||4.94|
|Net debt to EBITDA||-11.39||-4.53||-19.42||-15.41||9.55|
|Sales general and administrative to revenue||0.36||0.42||0.34||0.28||0.25|
|Research and developement to revenue||0.03||0.03||0.02||0.01||0.02|
|Intangibles to total assets||0.4||0.41||0.08||0.05||0.03|
|Capex to operating cash flow||0.02||0.02||0.01||0.71||-0.06|
|Capex to revenue||0||-0.01||0||-0.02||-0.01|
|Capex to depreciation||-0.02||-0.08||-0.06||-0.55||-0.18|
|Stock based compensation to revenue||0.03||0.04||0.06||0.02||0.02|
|Return on tangible assets||-0.09||-0.19||-0.09||-0.09||0.02|
|Tangible asset value||-59.53M||-62.6M||-62.77M||-63.93M||-63.08M|
|Net current asset value||-69.58M||-72.18M||-64.15M||-66.9M||-65.93M|
|Days sales outstanding||62.8||62.04||52.67||54.35||43.19|
|Days payables outstanding||66.05||54.18||37.65||28.46||37|
|Days of inventory on hand||34.42||30.88||32.44||33.17||27.46|
|Capex per share||0||-0.02||-0.01||-0.05||-0.02|
IDXG Frequently Asked Questions
What is Interpace Biosciences, Inc. stock symbol ?
Interpace Biosciences, Inc. is a US stock , located in Parsippany of Nj and trading under the symbol IDXG
What is Interpace Biosciences, Inc. stock quote today ?
Interpace Biosciences, Inc. stock price is $2.65 today.
Is Interpace Biosciences, Inc. stock public?
Yes, Interpace Biosciences, Inc. is a publicly traded company.